Cargando…
A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark
BACKGROUND: Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant disorder characterized by several clinical symptoms including epistaxis, arteriovenous malformations (AVM), and telangiectasia. In 2018, European Reference Network for Rare Vascular Diseases (VASCERN) recommended five...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734368/ https://www.ncbi.nlm.nih.gov/pubmed/34991676 http://dx.doi.org/10.1186/s13023-021-02160-1 |
_version_ | 1784628003627597824 |
---|---|
author | Hvelplund, Troels Lange, Bibi Bird, Susanne Djernes Korsholm, Malene Kjeldsen, Anette Drøhse |
author_facet | Hvelplund, Troels Lange, Bibi Bird, Susanne Djernes Korsholm, Malene Kjeldsen, Anette Drøhse |
author_sort | Hvelplund, Troels |
collection | PubMed |
description | BACKGROUND: Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant disorder characterized by several clinical symptoms including epistaxis, arteriovenous malformations (AVM), and telangiectasia. In 2018, European Reference Network for Rare Vascular Diseases (VASCERN) recommended five outcome measures for HHT-patients to guide health care providers, some with limited experience in treating HHT, and thereby maximizing the number of HHT-patients receiving good care. The outcome measures cover the following aspects: (1) 90% of the patients should receive a pulmonary AVM (PAVM) screening; (2) 90% of the patients should receive written advice on nosebleed; (3) 70% should be assessed for iron deficiency; (4) 100% of the patients should receive written advice on antibiotic (AB) prophylaxis prior to dental and surgical procedures, and (5) 100% of relevant patients should receive written advice on pregnancy. We have introduced the outcome measures as Benchmarks in our HHT-centre and wanted to evaluate the extend of implementation we have achieved. We constantly struggle to secure the best possible treatment of our HHT-patients. METHODS: The study was a non-interventional retrospective study. Data was collected manually from patient records and from the Danish HHT-database. RESULTS: A total of 180 HHT-patients were included, all diagnosed in the period from January 1st, 2016, to December 31st, 2020. All patients were screened for PAVM. We could confirm that 66% of patients who had epistaxis received thoroughly advice. Assessment for iron deficiency was performed in 80% of the adult patients. Thoroughly advice on AB prophylaxis was documented in 75%. Thoroughly advice on pregnancy was documented in 80% of female patients 15–45 years of age. There were no significant differences over time for any of the outcome measures. CONCLUSIONS: The Danish HHT-centre reached the target threshold for outcome measures 1 and 3. It could not be documented that the target thresholds for outcome measures 2, 4, and 5 were achieved. As information and education are a very important part of HHT care, focus on and documentation that all patients receive the relevant advice must be a priority in order to ensure best care. |
format | Online Article Text |
id | pubmed-8734368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87343682022-01-07 A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark Hvelplund, Troels Lange, Bibi Bird, Susanne Djernes Korsholm, Malene Kjeldsen, Anette Drøhse Orphanet J Rare Dis Research BACKGROUND: Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant disorder characterized by several clinical symptoms including epistaxis, arteriovenous malformations (AVM), and telangiectasia. In 2018, European Reference Network for Rare Vascular Diseases (VASCERN) recommended five outcome measures for HHT-patients to guide health care providers, some with limited experience in treating HHT, and thereby maximizing the number of HHT-patients receiving good care. The outcome measures cover the following aspects: (1) 90% of the patients should receive a pulmonary AVM (PAVM) screening; (2) 90% of the patients should receive written advice on nosebleed; (3) 70% should be assessed for iron deficiency; (4) 100% of the patients should receive written advice on antibiotic (AB) prophylaxis prior to dental and surgical procedures, and (5) 100% of relevant patients should receive written advice on pregnancy. We have introduced the outcome measures as Benchmarks in our HHT-centre and wanted to evaluate the extend of implementation we have achieved. We constantly struggle to secure the best possible treatment of our HHT-patients. METHODS: The study was a non-interventional retrospective study. Data was collected manually from patient records and from the Danish HHT-database. RESULTS: A total of 180 HHT-patients were included, all diagnosed in the period from January 1st, 2016, to December 31st, 2020. All patients were screened for PAVM. We could confirm that 66% of patients who had epistaxis received thoroughly advice. Assessment for iron deficiency was performed in 80% of the adult patients. Thoroughly advice on AB prophylaxis was documented in 75%. Thoroughly advice on pregnancy was documented in 80% of female patients 15–45 years of age. There were no significant differences over time for any of the outcome measures. CONCLUSIONS: The Danish HHT-centre reached the target threshold for outcome measures 1 and 3. It could not be documented that the target thresholds for outcome measures 2, 4, and 5 were achieved. As information and education are a very important part of HHT care, focus on and documentation that all patients receive the relevant advice must be a priority in order to ensure best care. BioMed Central 2022-01-06 /pmc/articles/PMC8734368/ /pubmed/34991676 http://dx.doi.org/10.1186/s13023-021-02160-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Hvelplund, Troels Lange, Bibi Bird, Susanne Djernes Korsholm, Malene Kjeldsen, Anette Drøhse A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark |
title | A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark |
title_full | A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark |
title_fullStr | A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark |
title_full_unstemmed | A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark |
title_short | A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark |
title_sort | retrospective cohort study on european reference network for rare vascular diseases 5 outcome measures for hereditary haemorrhagic telangiectasia in denmark |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734368/ https://www.ncbi.nlm.nih.gov/pubmed/34991676 http://dx.doi.org/10.1186/s13023-021-02160-1 |
work_keys_str_mv | AT hvelplundtroels aretrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark AT langebibi aretrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark AT birdsusannedjernes aretrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark AT korsholmmalene aretrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark AT kjeldsenanettedrøhse aretrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark AT hvelplundtroels retrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark AT langebibi retrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark AT birdsusannedjernes retrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark AT korsholmmalene retrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark AT kjeldsenanettedrøhse retrospectivecohortstudyoneuropeanreferencenetworkforrarevasculardiseases5outcomemeasuresforhereditaryhaemorrhagictelangiectasiaindenmark |